X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13527) 13527
Publication (1165) 1165
Book Review (125) 125
Dissertation (38) 38
Book Chapter (35) 35
Conference Proceeding (12) 12
Government Document (8) 8
Data Set (6) 6
Magazine Article (5) 5
Web Resource (4) 4
Book / eBook (2) 2
Paper (2) 2
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cyclooxygenase-2 (8548) 8548
humans (5995) 5995
index medicus (5661) 5661
animals (5121) 5121
male (3476) 3476
inflammation (2985) 2985
female (2745) 2745
mice (2652) 2652
expression (2515) 2515
oncology (2437) 2437
cox-2 inhibitors (2377) 2377
cyclooxygenase 2 - metabolism (2260) 2260
celecoxib (2120) 2120
pharmacology & pharmacy (2115) 2115
rats (2024) 2024
nonsteroidal antiinflammatory drugs (1978) 1978
apoptosis (1930) 1930
cancer (1928) 1928
cox-2 (1671) 1671
cyclooxygenase 2 (1549) 1549
biochemistry & molecular biology (1482) 1482
cyclooxygenase-2 expression (1450) 1450
prostaglandin endoperoxide synthase (1346) 1346
inhibition (1344) 1344
middle aged (1295) 1295
cyclooxygenase-2 inhibitor (1256) 1256
cell biology (1225) 1225
activation (1220) 1220
cyclooxygenase inhibitors - pharmacology (1206) 1206
nitric-oxide synthase (1193) 1193
gene expression (1182) 1182
rodents (1134) 1134
proteins (1129) 1129
cells (1113) 1113
cyclooxygenase 2 - genetics (1100) 1100
cell line, tumor (1079) 1079
aged (1071) 1071
analysis (1058) 1058
adult (1050) 1050
nf-kappa-b (1037) 1037
cyclooxygenase 2 inhibitors - pharmacology (1015) 1015
research (1009) 1009
cyclooxygenase-2 inhibitors (995) 995
membrane proteins (995) 995
cytokines (985) 985
sulfonamides - pharmacology (985) 985
nitric oxide (952) 952
dose-response relationship, drug (938) 938
signal transduction (907) 907
chemistry, medicinal (901) 901
research article (901) 901
medicine (893) 893
anti-inflammatory agents, non-steroidal - pharmacology (876) 876
prostaglandins (868) 868
cyclooxygenase 2 inhibitors (852) 852
kinases (836) 836
immunohistochemistry (808) 808
immunology (807) 807
prostaglandin e2 (806) 806
gene-expression (799) 799
enzymes (797) 797
oxidative stress (784) 784
prostaglandin-endoperoxide synthases - metabolism (783) 783
anti-inflammatory agents, non-steroidal - therapeutic use (781) 781
prostaglandin e-2 (766) 766
cells, cultured (759) 759
in-vitro (758) 758
apoptosis - drug effects (755) 755
nonsteroidal anti-inflammatory drugs (740) 740
angiogenesis (737) 737
multidisciplinary sciences (737) 737
phosphorylation (734) 734
medicine, research & experimental (730) 730
rheumatoid-arthritis (726) 726
inhibitors (711) 711
cell line (709) 709
health aspects (709) 709
macrophages (705) 705
dinoprostone - metabolism (699) 699
disease models, animal (699) 699
care and treatment (694) 694
science (693) 693
article (687) 687
prevention (671) 671
growth (661) 661
aspirin (660) 660
rats, sprague-dawley (659) 659
tumors (654) 654
colorectal-cancer (646) 646
cyclooxygenase inhibitors - therapeutic use (637) 637
risk factors (637) 637
risk (625) 625
neurosciences (623) 623
rofecoxib (620) 620
blotting, western (619) 619
studies (616) 616
cell proliferation - drug effects (607) 607
cyclooxygenase (606) 606
anti-inflammatory agents, non-steroidal - adverse effects (603) 603
gastroenterology & hepatology (595) 595
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13388) 13388
Japanese (56) 56
German (46) 46
French (43) 43
Korean (22) 22
Chinese (21) 21
Spanish (19) 19
Russian (12) 12
Portuguese (7) 7
Polish (6) 6
Croatian (2) 2
Persian (2) 2
Turkish (2) 2
Czech (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 10/2017, Volume 26, Issue 10, pp. 1141 - 1148
Purpose To assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti‐inflammatory... 
proton pump inhibitors | bleeding | gastrointestinal toxicity | perforation | selective COX‐2 inhibitors | ulcers | conventional NSAIDs | selective COX-2 inhibitors | RHEUMATOID-ARTHRITIS | CARDIOVASCULAR EVENTS | NONSELECTIVE NSAIDS | CELECOXIB | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CONTROLLED TRIALS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | CYCLOOXYGENASE-2 INHIBITORS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | Age Factors | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Peptic Ulcer - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Case-Control Studies | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Pain - drug therapy | Pain Management - adverse effects | Aged, 80 and over | Female | Odds Ratio | Peptic Ulcer - complications | Risk Factors | Pain Management - methods | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peptic Ulcer Perforation - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Aged | Peptic Ulcer - chemically induced | Peptic Ulcer Perforation - etiology | COX-2 inhibitors | Proton pump inhibitors | Nonsteroidal anti-inflammatory drugs | Drugs | Antiinflammatory agents | Control methods | Adjustment | Toxicity | Perforation | Pharmacology | Inflammation | Regression analysis | Patients | Risk factors | Bleeding | Confidence intervals | Inhibitors | Ulcers | Cyclooxygenase-2 | Health risk assessment | Index Medicus | Original Report | Original Reports
Journal Article
Journal Article
Oncology Reports, ISSN 1021-335X, 11/2017, Volume 38, Issue 5, pp. 2657 - 2666
Chemotherapy is one of the most effective non-surgical treatments for various types of tumor. Identifying different combinations of antitumor agents that can... 
PGE2 | COX-2 | celecoxib | PTEN | AKT | HDAC6 inhibitor | HDAC | Celecoxib | CANCER CELLS | ACETYLATION | PANCREATIC-CANCER | RECEPTOR | BREAST-CANCER | INVASION | ONCOLOGY | CYCLOOXYGENASE-2 INHIBITORS | MALIGNANCIES | EXPRESSION | HISTONE DEACETYLASE | Celecoxib - administration & dosage | Humans | Transcriptional Activation - drug effects | Histone Deacetylase Inhibitors - administration & dosage | Indoles - administration & dosage | Glioblastoma - genetics | Hydroxamic Acids - administration & dosage | Glioblastoma - metabolism | Indoles - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Hydroxamic Acids - pharmacology | Cell Survival - drug effects | PTEN Phosphohydrolase - genetics | Cyclooxygenase 2 Inhibitors - pharmacology | Cyclooxygenase 2 Inhibitors - administration & dosage | PTEN Phosphohydrolase - metabolism | Celecoxib - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Anilides - administration & dosage | Anilides - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Mice | Mutation | Glioblastoma - drug therapy | Care and treatment | Cellular signal transduction | Enzyme inhibitors | Health aspects | Methods | Cancer | Immunoglobulins | Phosphorylation | Lung cancer | Breast cancer | Kinases | Cancer therapies | Proteins | Cell growth | Chemotherapy | Protein expression | Tumors | Apoptosis
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 09/2019, Volume 32, Issue 5, pp. 687 - 696
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 2012, Volume 47, Issue 1, pp. 111 - 124
Balanced modulation of several targets is one of the current strategies for the treatment of multi-factorial diseases. Based on the knowledge of inflammation... 
Multi-target drugs | Benzo/benzisothiazolidinones | Inflammation | Lipoxygenase inhibitors | COX-1/2 inhibitors | Fragment-based drug design | CHEMISTRY, MEDICINAL | CYCLOOXYGENASE-2 | MECHANISM | CRYSTAL-STRUCTURE | LIPOXYGENASES | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | COX-2 INHIBITORS | DUAL INHIBITORS | DERIVATIVES | ANTIMICROBIAL ACTIVITY | LIGAND DESIGN | Thiazolidines - chemical synthesis | Thiazolidines - metabolism | Male | Structure-Activity Relationship | Anti-Inflammatory Agents - metabolism | Lipoxygenase - metabolism | Lipoxygenase Inhibitors - chemical synthesis | Lipoxygenase Inhibitors - chemistry | Drug Design | Cyclooxygenase 1 - chemistry | Female | Thiazolidines - pharmacology | Thiazolidines - chemistry | Catalytic Domain | Cyclooxygenase Inhibitors - metabolism | Anti-Inflammatory Agents - pharmacology | Cyclooxygenase 2 - chemistry | Models, Molecular | Cyclooxygenase Inhibitors - chemistry | Edema - drug therapy | Lipoxygenase - chemistry | Cyclooxygenase Inhibitors - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Anti-Inflammatory Agents - chemical synthesis | Lipoxygenase Inhibitors - metabolism | Mice | Cyclooxygenase 1 - metabolism | Edema - chemically induced | Lipoxygenase Inhibitors - pharmacology | COX-2 inhibitors | Enzymes
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, p. e0139212
Background Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a... 
IBUPROFEN | ENZYME | COX-2 | OXYGENATION | ENDOCANNABINOIDS | MULTIDISCIPLINARY SCIENCES | ANANDAMIDE | INDOMETHACIN | FLURBIPROFEN | LINEAR-MODELS | ANTIINFLAMMATORY DRUGS | Endocannabinoids - metabolism | Stereoisomerism | Humans | Brain - enzymology | Male | Arachidonic Acids - metabolism | Isoenzymes - metabolism | Benzamides - pharmacology | Carbamates - pharmacology | Amides - pharmacology | Amidohydrolases - metabolism | Amidohydrolases - antagonists & inhibitors | Polyunsaturated Alkamides - metabolism | Cyclooxygenase Inhibitors - pharmacology | Hydrolysis | Animals | Arachidonic Acid - pharmacology | Cyclooxygenase 2 - metabolism | Lipid Metabolism - drug effects | Lipopolysaccharides - pharmacology | Amides - chemistry | Ionomycin - pharmacology | RAW 264.7 Cells | Mice | Cyclooxygenase 1 - metabolism | Flurbiprofen - pharmacology | Interferon-gamma - pharmacology | Prostaglandins - metabolism | Brain | COX-2 inhibitors | Neurosciences | Lipids | Enantiomers | Arachidonic acid | Macrophages | Prostaglandin endoperoxide synthase | Pain | 2-Arachidonylglycerol | Rodents | Nonsteroidal anti-inflammatory drugs | Flurbiprofen | Functional foods & nutraceuticals | Fatty-acid amide hydrolase | Enzymes | Hydrolase | Substrate inhibition | Pharmacology | Prostaglandin D2 | Fatty acids | Substrates | Anandamide | Environmental science | Inhibitors | Cyclooxygenase-1 | Interferon | Cyclooxygenase-2 | Oxygenation | Pharmaceuticals | Basic Medicine | Farmakologi och toxikologi | Medical and Health Sciences | Pharmacology and Toxicology | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Immunology, ISSN 0022-1767, 06/2000, Volume 164, Issue 12, pp. 6509 - 6519
Resveratrol (trans-3,4',5-trihydroxystilbene), a polyphenolic phytoalexin found in grapes, fruits, and root extracts of the weed Polygonum cuspidatum, exhibits... 
SIGNAL-TRANSDUCTION | TUMOR-NECROSIS-FACTOR | NITRIC-OXIDE SYNTHASE | C-JUN KINASE | GENE-EXPRESSION | CYCLOOXYGENASE-2 EXPRESSION | DEPENDENT APOPTOSIS | RED WINE | IMMUNOLOGY | CORONARY HEART-DISEASE | FACTOR-ALPHA | Okadaic Acid - pharmacology | Reactive Oxygen Species - metabolism | Tetradecanoylphorbol Acetate - pharmacology | Apoptosis - drug effects | Humans | Transcription Factor RelA | NF-kappa B - metabolism | Lipopolysaccharides - antagonists & inhibitors | Stilbenes - pharmacology | Transcription Factor AP-1 - metabolism | DNA-Binding Proteins - metabolism | Reactive Oxygen Species - physiology | Cell Nucleus - metabolism | Lipid Peroxidation - drug effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Resveratrol | JNK Mitogen-Activated Protein Kinases | Biological Transport - drug effects | Phosphorylation - drug effects | Cytotoxicity, Immunologic - drug effects | Immunosuppressive Agents - pharmacology | Cell Line | NF-KappaB Inhibitor alpha | NF-kappa B - antagonists & inhibitors | DNA-Binding Proteins - antagonists & inhibitors | NF-kappa B p50 Subunit | Okadaic Acid - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Hydrogen Peroxide - pharmacology | I-kappa B Proteins | Ceramides - antagonists & inhibitors | Caspase Inhibitors | Ceramides - pharmacology | Gene Expression Regulation - drug effects | Tumor Necrosis Factor-alpha - pharmacology | Transcription Factor AP-1 - antagonists & inhibitors | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Genes, Reporter - drug effects | Cell Nucleus - drug effects | Hydrogen Peroxide - antagonists & inhibitors | MAP Kinase Kinase Kinase 1 | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article